摘要
目的探讨非小细胞肺癌(NSCLC)中RhoB和E-钙黏蛋白(E-cadherin)的表达及其临床意义。方法采用免疫组化Super Pic TureTMPolymer二步法,检测116例NSCLC组织(NSCLC组)和同期116例正常余肺组织(正常组)中RhoB和E-cadherin的表达,并分析其表达与患者临床病理特征及预后的关系。结果 NSCLC组RhoB、E-cadherin阳性表达率均低于正常组(57.76%vs 87.07%,54.31%vs 85.34%,均P<0.01)。NSCLC组织中RhoB的表达强度在不同肿瘤病理类型、肿瘤分化程度及淋巴结转移情况间的差异有统计学意义,E-cadherin的表达强度在不同TNM分期、肿瘤分化程度及淋巴结转移情况间的差异有统计学意义。NSCLC组RhoB与E-cadherin的表达呈正相关(r=0.503,P<0.01)。RhoB高表达的患者3年生存率高于低表达者(83.93%vs 40.00%,Log-rankχ2=18.992,P<0.01);Ecadherin高表达的患者3年生存率高于低表达者(85.11%vs 44.93%,Log-rankχ2=16.680,P<0.01)。RhoB和E-cadherin共同低表达、淋巴结转移是影响NSCLC患者预后的危险因素。结论 RhoB与E-cadherin在NSCLC组织中的表达呈现较好的相关性,检测二者的表达对判断NSCLC患者的临床病理学特征及预后有一定提示作用。
Objective To investigate the expressions of RhoB and E-cadherin in non-small-cell lung cancer （NSCLC）, and their clinical significances thereof. Methods Immunohistochemical staining was applied to detect expres- sions of RhoB and E-cadherin in 116 samples of NSCLC （NSCLC group） and 116 samples of normal lung tissues （control group）. Correlations of expressions of RhoB and E-cadherin to clinical pathological parameters and prognosis were analyzed in two groups. Results The expression intensities of RhoB and E-cadherin were significantly lower in NSCLC group than those in control group （57.76% vs 87.07%, 54.31% vs 85.34%, P 〈 0.01）. There were significant differences in the expres- sion of RboB between different pathological types, differentiation and lymph node metastasis in NSCLC group. There were significant differences in the expression of E-cadherin between different TNM stages, differentiation and lymph node metas- tasis in NSCLC group. The expression of RhoB was positively correlated with the expression of E-cadherin （r=0.503, P 〈 0.01）. The 3-year survival rates were significantly higher in patients with high expression of RhoB （83.93%） than those in pa- tients with low expression of RhoB （40.00%, Log-rank X~=18.992, P 〈 0.01）. The 3-year survival rates were significantly higher in patients with high expression of E-cadherin （85.11%） than those in patients with low expression of E-cadherin （44.93%, Log-rank X2=16.680, P 〈 0.01）. Further multivariate analysis suggested that both lower expressions of RhoB and E-cadherin and lymph node metastasis were prognostic indicators for NSCLC （P 〈 0.001）. Conclusion The expressions of RhoB and E-cadherin showed a good correlation in NSCLC. Detecting the expression of RhoB combined with E-cadherin may give a clue on clinicopathological features and prognosis in patients with NSCLC.
出处
《天津医药》
CAS
北大核心
2014年第1期27-30,I0003,共5页
Tianjin Medical Journal
